OBJECTIVE: To estimate rates of progression from mild cognitive impairment (MCI) to dementia and of reversion from MCI to being cognitively normal (CN) in a population-based cohort. METHODS: Participants (n = 534, aged 70 years and older) enrolled in the prospective Mayo Clinic Study of Aging were evaluated at baseline and every 15 months to identify incident MCI or dementia. RESULTS: Over a median follow-up of 5.1 years, 153 of 534 participants (28.7%) with prevalent or incident MCI progressed to dementia (71.3 per 1,000 person-years). The cumulative incidence of dementia was 5.4% at 1 year, 16.1% at 2, 23.4% at 3, 31.1% at 4, and 42.5% at 5 years. The risk of dementia was elevated in MCI cases (hazard ratio [HR] 23.2, p < 0.001) compared with CN subjects. Thirty-eight percent (n = 201) of MCI participants reverted to CN (175.0/1,000 person-years), but 65% subsequently developed MCI or dementia; the HR was 6.6 (p < 0.001) compared with CN subjects. The risk of reversion was reduced in subjects with an APOE ε4 allele (HR 0.53, p < 0.001), higher Clinical Dementia Rating Scale-Sum of Boxes (HR 0.56, p < 0.001), and poorer cognitive function (HR 0.56, p < 0.001). The risk was also reduced in subjects with amnestic MCI (HR 0.70, p = 0.02) and multidomain MCI (HR 0.61, p = 0.003). CONCLUSIONS: MCI cases, including those who revert to CN, have a high risk of progressing to dementia. This suggests that diagnosis of MCI at any time has prognostic value.
OBJECTIVE: To estimate rates of progression from mild cognitive impairment (MCI) to dementia and of reversion from MCI to being cognitively normal (CN) in a population-based cohort. METHODS:Participants (n = 534, aged 70 years and older) enrolled in the prospective Mayo Clinic Study of Aging were evaluated at baseline and every 15 months to identify incident MCI or dementia. RESULTS: Over a median follow-up of 5.1 years, 153 of 534 participants (28.7%) with prevalent or incident MCI progressed to dementia (71.3 per 1,000 person-years). The cumulative incidence of dementia was 5.4% at 1 year, 16.1% at 2, 23.4% at 3, 31.1% at 4, and 42.5% at 5 years. The risk of dementia was elevated in MCI cases (hazard ratio [HR] 23.2, p < 0.001) compared with CN subjects. Thirty-eight percent (n = 201) of MCI participants reverted to CN (175.0/1,000 person-years), but 65% subsequently developed MCI or dementia; the HR was 6.6 (p < 0.001) compared with CN subjects. The risk of reversion was reduced in subjects with an APOE ε4 allele (HR 0.53, p < 0.001), higher Clinical Dementia Rating Scale-Sum of Boxes (HR 0.56, p < 0.001), and poorer cognitive function (HR 0.56, p < 0.001). The risk was also reduced in subjects with amnestic MCI (HR 0.70, p = 0.02) and multidomain MCI (HR 0.61, p = 0.003). CONCLUSIONS: MCI cases, including those who revert to CN, have a high risk of progressing to dementia. This suggests that diagnosis of MCI at any time has prognostic value.
Authors: Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: M E Peters; P B Rosenberg; M Steinberg; M C Norton; K A Welsh-Bohmer; K M Hayden; J Breitner; J T Tschanz; C G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: L Fratiglioni; L J Launer; K Andersen; M M Breteler; J R Copeland; J F Dartigues; A Lobo; J Martinez-Lage; H Soininen; A Hofman Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: Tobias Luck; Melanie Luppa; Birgit Wiese; Wolfgang Maier; Hendrik van den Bussche; Marion Eisele; Frank Jessen; Dagmar Weeg; Siegfried Weyerer; Michael Pentzek; Hanna Leicht; Mirjam Koehler; Franziska Tebarth; Julia Olbrich; Sandra Eifflaender-Gorfer; Angela Fuchs; Hans-Helmut Koenig; Steffi G Riedel-Heller Journal: Am J Geriatr Psychiatry Date: 2012-11 Impact factor: 4.105
Authors: Oscar L Lopez; James T Becker; Yue-Fang Chang; Robert A Sweet; Steven T DeKosky; Michael H Gach; Owen T Carmichael; Eric McDade; Lewis H Kuller Journal: Neurology Date: 2012-09-26 Impact factor: 9.910
Authors: S Larrieu; L Letenneur; J M Orgogozo; C Fabrigoule; H Amieva; N Le Carret; P Barberger-Gateau; J F Dartigues Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky Journal: J Neuropsychiatry Clin Neurosci Date: 2000 Impact factor: 2.198
Authors: Maria Vassilaki; Jeremiah A Aakre; Ruth H Cha; Walter K Kremers; Jennifer L St Sauver; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Ronald C Petersen; Rosebud O Roberts Journal: J Am Geriatr Soc Date: 2015-08-27 Impact factor: 5.562
Authors: David S Knopman; Rosebud O Roberts; V Shane Pankratz; Ruth H Cha; Walter A Rocca; Michelle M Mielke; Bradley F Boeve; Eric G Tangalos; Robert J Ivnik; Yonas E Geda; Ronald C Petersen Journal: Am J Epidemiol Date: 2014-05-23 Impact factor: 4.897
Authors: Mary Ganguli; Ching-Wen Lee; Beth E Snitz; Tiffany F Hughes; Eric McDade; Chung-Chou H Chang Journal: Neurology Date: 2014-12-03 Impact factor: 9.910
Authors: Anders Wallin; Arto Nordlund; Michael Jonsson; Karin Lind; Åke Edman; Mattias Göthlin; Jacob Stålhammar; Marie Eckerström; Silke Kern; Anne Börjesson-Hanson; Mårten Carlsson; Erik Olsson; Henrik Zetterberg; Kaj Blennow; Johan Svensson; Annika Öhrfelt; Maria Bjerke; Sindre Rolstad; Carl Eckerström Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Mary Hannan; Alana Steffen; Lauretta Quinn; Eileen G Collins; Shane A Phillips; Ulf G Bronas Journal: J Nephrol Date: 2018-05-25 Impact factor: 3.902
Authors: P J Schulte; R O Roberts; D S Knopman; R C Petersen; A C Hanson; D R Schroeder; T N Weingarten; D P Martin; D O Warner; J Sprung Journal: Br J Anaesth Date: 2018-06-27 Impact factor: 9.166
Authors: Mary M Machulda; V Shane Pankratz; Teresa J Christianson; Robert J Ivnik; Michelle M Mielke; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Ronald C Petersen Journal: Clin Neuropsychol Date: 2013-09-17 Impact factor: 3.535